Brookline Capital's Positive Outlook on Immunic's MS Drug Candidate IMU-838 Sparks Buy Rating
Friday, 5 April 2024, 17:00
Brookline Capital's Coverage of Immunic (IMUX)
Brookline Capital Markets recently initiated coverage of Immunic with a buy rating, focusing on the company's multiple sclerosis drug candidate IMU-838. The analysis showcases Immunic's potential in the market and the effectiveness of their drug in treating MS patients.
- Positive outlook on Immunic's MS drug candidate
- Highlighted potential of IMU-838 in multiple sclerosis treatment
- Initiation of a buy rating by Brookline Capital Markets
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.